Objective: Totally endoscopic coronary artery bypass grafting was shown to be feasible and safe, with excellent clinical and angiographic mid-term results. Data on long-term outcome are lacking. Therefore, we aimed to investigate the long-term rate of major adverse cardiac and cerebrovascular events and left internal mammary artery patency rate in patients undergoing arrested heart totally endoscopic coronary artery bypass grafting. Methods: From 2001 to 2012, a total of 208 arrested heart-totally endoscopic coronary artery bypass grafting patients were prospectively included. Mean ± SD age was 58.8 ± 9.4 years, and mean ± SD Society of Thoracic Surgeons score was 0.5 ± 0.5%. Major adverse cardiac and cerebrovascular events were defined as a composite of death, myocardial infarction, stroke, re-percutaneous coronary intervention, re-coronary artery bypass graft, and target vessel revascularization. Left internal mammary artery patency was assessed using cardiac computed tomography and depicted according to the established Fitzgibbon classification. Mean ± SD follow-up was 6.9 ± 2.3 years. Results: At 1, 5, and 10 years, survival rate was 100%, 98.3%, and 95.8%, respectively. The freedom from clinical events at 1, 5, and 10 years were major adverse cardiac and cerebrovascular events (93.5%, 85.9%, and 83.0%), myocardial infarction (99.0%, 97.4%, and 95.9%), target vessel revascularization (96.0%, 94.3%, and 91.7%), re-percutaneous coronary intervention (94.5%, 91.6%, and 84.2%), and re-coronary artery bypass graft (100%, 99.5%, and 99.5%), respectively. Left internal mammary artery patency rate at 1, 5, and 10 years was 100%, 94.9%, and 88.1%, respectively. Conclusions: Arrested heart-totally endoscopic coronary artery bypass grafting shows excellent clinical long-term results with a left internal mammary artery patency rate comparable with conventional coronary artery bypass graft at 10 years after surgery.
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One of the main factors contributing to improve long-term survival after CABG is the excellent patency rate of the left internal mammary artery (LIMA), especially when used to bypass lesions in the left anterior descending artery (LAD). 2, 3 Most CABG operations are performed through median sternotomy, coming along with access related serious complications due to invasiveness. 4 Therefore, less invasive techniques for coronary revascularization were developed during the last decade. Totally endoscopic coronary artery bypass grafting (TECAB) was shown to be a feasible and safe minimally invasive option for selected patients. 5 The complete preservation of thoracic integrity leads to an improvement in quality of life and to a more rapid restoration of daily activities. 6 Furthermore, excellent results regarding mid-term clinical and angiographic results of TECAB are reported. [7] [8] [9] [10] However, data on long-term clinical and angiographic outcome are still missing. Therefore, we aimed to investigate the long-term rate of major adverse cardiac and cerebrovascular events (MACCEs) and the long-term LIMA patency rate in a large cohort of arrested heart (AH) TECAB patient.
METHODS

Patient Population
From 2001 to 2012, a total of 208 consecutive AH-TECAB patients from a single center were prospectively enrolled in our study. All patients underwent routine preoperative clinical assessment including coronary angiography, computed tomography (CT) and echocardiography. The indication for AH-TECAB was single-or double-vessel coronary artery disease involving LAD territory not eligible for percutaneous coronary intervention (PCI). Contraindications were previous cardiac surgery, renal insufficiency with creatinine level of greater than 2 mg/dL; active infection; life expectancy of less than 1 year due to other illness; uncontrolled acute myocardial ischemia; and recent cerebrovascular accident. Furthermore, all circumstances preventing remote access perfusion, such as minimal lumen diameter of the femoroiliac vessels of less than 6 mm, severe kinking or calcifications of the peripheral vessels, severe calcification aneurysm or thrombus formation of the abdominal, descending or ascending aorta, maximal diameter of the ascending aorta of greater than 40 mm, and aortic valve regurgitation of more than moderate, were considered as contraindication for AH-TECAB. Written informed consent was obtained from all patients. The study was approved by the local ethic committee and is in line with the Declaration of Helsinki.
Study End Points
The end points of our study were the rate of survival and MACCE at 1, 5, and 10 year and the long-term patency rate of LIMA-LAD bypass during follow-up. MACCE was defined as composite of death, myocardial infarction, stroke, re-PCI, re-CABG, and any form of target vessel revascularization. Clinical follow-up was conducted via an outpatient visit or by telephone interview performed by medical personnel blinded to study relevant data.
Computed Tomography Angiography
Patency rate was evaluated with cardiac CT (cCT) using a 128-slice dual-source CT scanner. Patients were scanned in supine position in midinspiration breath-hold. Different scan protocols were applied primarily based on patient's heart rate: prospective electrocardiography triggering was used for heart rate of less than 65 beats per minute (bpm); with greater than 65 bpm or irregular heart rate, retrospective electrocardiography gating was used. Depending on individual patient's body weight, the contrast agent ranged between 65 and 120 millilitres following a standardized scheme. All images were reviewed by an experienced radiologist. An example of a coronary CT image is given in Figure 1 . Eligible candidates were defined as single LIMA to LAD bypass procedures. Before cCT scan, patients underwent clinical examination and laboratory testing. The primary exclusion criteria for cCT scan were contrast agent allergy, chronic kidney disease with a glomerular filtration rate of less than 50 mL/min per square meter, medically treated thyroid disorders, and missing patients' informed consent.
Patency Rate Classification
Graft patency rates were divided into the following three grades according to Fitzgibbon classification: grade A was defined as completely open or a stenosis of less than 50%, grade B as stenosis reducing the diameter more than 50%, and grade 0 as total occlusion.
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Operative Technique
The operative and technical details of AH-TECAB have been published previously. 12, 13 Briefly, the procedure is performed with femoral cannulation for cardiopulmonary bypass and endoballoon occlusion of the ascending aorta. The lung is ventilated unilaterally via double-lumen tube. Three to four trocars of the da Vinci robotic system (Intuitive Surgical, Sunnyvale, CA USA) are inserted in the left hemithorax. After endoscopic IMA harvesting, cardiac arrest can be initiated with antegrade cardioplegia solution through a distal channel of the endoballoon catheter. Suturing of the CABG anastomosis can be performed very precisely with the robotic telemanipulation system at the arrested heart.
Statistical Analysis
Statistical analysis was performed with SPSS Statistics Version 24 (IBM, Armonk, NY USA). Continuous data are expressed as means ± SD, and discrete data are expressed as numbers with corresponding percentages. Time-dependent outcomes were plotted by Kaplan-Meier graphs. Comparison of outcomes between converted and nonconverted patients were performed by log-rank test. A two-tailed P value of less than 0.05 was defined to indicate statistical significance. To overcome selection bias, all analyses were performed on an intention to treat basis.
RESULTS
Patient Baseline Characteristics
From 2001 to 2012, 208 cases of robotic AH-TECAB were performed in our center. Mean ± SD age of the cohort was 58.8 ± 9.4 years, and mean ± SD Society of Thoracic Surgeons score was 0.5 ± 0.5%. Fifty patients (24%) were female. Mean ± SD number of diseased coronary vessels was 1.4 ± 0.6. Nine patients (4.3%) had left main disease. Hybrid revascularizations were performed in 56 patients (26.9%). Preoperative patient characteristics are shown in Table 1 .
Graft Configuration
One hundred seventy-eight procedures (86%) were IMA to LAD TECAB, of which 148 (71%) were isolated LIMA to LAD. Bilateral IMA was used in 30 patients (14%). Of these, 26 procedures (13%) were RIMA to LAD and LIMA to circumflex artery. Single IMA graft was used three times (1.5%) to circumflex artery as well as three times (1.5%) to right coronary artery, and in 12 cases (6%), IMA was used as sequential graft.
Perioperative Results
Mean ± SD operative time was 348 ± 126 minutes. Mean ± SD cardiopulmonary bypass time 120 ± 67 minutes and aortic cross clamp time was 75 ± 43 minutes. Conversion to median sternotomy and conventional operative technique occurred in 25 cases (12%). Five patients had bleeding of the anastomosis; two patients needed revision after intraoperative angiography caused by limited flow of the graft anastomosis; in six patients, the installation of remote access perfusion with the endoballoon device was not possible; three patients were converted because the target vessel was not adjustable; in five procedures, problems with the arterial graft led to conversion; one patient had an intraoperative type A dissection; one conversion was caused by porthole bleeding; and in two procedures, adjacent structures were injured. Prolonged ventilation (>24 hours) was necessary in 18 patients (8.7%). Conversion to sternotomy had no impact on all investigated clinical study end points. There was no significant difference in survival (P = 0.700), MACCE (P = 0.786), and all other end points (all P > 0.05). New onset of renal failure requiring hemodialysis was observed in five patients (2.4%), and stroke was diagnosed in three patients (1.4%). Eighty-nine percent of the patients underwent intraoperative bypass graft angiography to confirm IMA patency. Two of them had relevant angiographic findings requiring an intraoperative revision. No perioperative mortality was observed. Perioperative results are shown in Table 2 .
Clinical Long-Term Follow-up Mean ± SD follow-up time was 6.9 ± 2.3 years. At 1, 5, and 10 years, the rate of survival was 99.5%, 98.3%, and 95.8% (Fig. 2) and freedom from MACCE was 93.5%, 85.9%, and 83% (Fig. 3) , respectively. Details contributing to the combined clinical end-point MACCE are depicted in Table 3 . Completeness of follow-up at 1, 5, and 10 years was 99%, 62%, and 14%, respectively. Table 4 is presenting a subgroup analysis of the clinical long-term follow-up of isolated LIMA to LAD bypass procedures. In this group, survival was 100%, 97.5%, and 95.1% at 1, 5, and 10 years, respectively.
Patency Rate
A total of 67 isolated LIMA to LAD bypass patients (45%) were included for cCT scan analysis. Beside our exclusion criteria for a cCT scan, 49 patients (33%) did not consent to a cCT scan. Mean ± SD time interval to cCT scan was 6.9 ± 2.8 years after the procedure with an overall patency rate (Table 5 ). During follow-up, one patient (0.5%) was classified as Fitzgibbon grade B and five patients (2.4%) as grade 0 (Table 6 ). Two patients (1%) had a graft occlusion due to competitive flow. Preoperatively, one of these had an in-stent restenosis, and the other one a stenosis of the native LAD. However, the preoperative stenosis of the native coronary vessel was no longer existing in the long-term cCT follow-up of these two patients.
DISCUSSION
The present study is the currently largest investigation of clinical and CT-angiographic outcome of patients undergoing AH-TECAB. The main findings can be summarized as follows: (a) long-term results in terms of survival and MACCE rate are encouraging (b) long-term patency rate of LIMA to LAD bypass is comparable with conventional CABG. 14, 15 In the last decade, minimally invasive CABG became an increasingly considerable alternative for myocardial revascularization in highly selected patients. In general, two procedures were developed to achieve a minimally invasive approach with advantages of less trauma and rapid postoperative recovery: minimally invasive direct coronary artery bypass (MIDCAB) and robotic TECAB. Minimally invasive direct coronary artery bypass is a well-established method with good perioperative and long-term results, although it is limited for the revascularization of the anterior wall. 16 Robotic techniques provide the opportunity of multivessel CABG with even smaller incisions. The safety and feasibility could be proofed in numerous previous publications. 5, 17, 18 In addition, excellent results regarding mid-term clinical and angiographic results of TECAB were described. [19] [20] [21] [22] Nevertheless, data regarding long-term clinical outcome are lacking. Furthermore, LIMA patency rate, which is known to significantly influence long-term survival, is unknown for patients undergoing AH-TECAB. Kappert et al. 22 reported the mid-term clinical outcomes after TECAB including 41 patients. Despite the survival rate of 93% after 5 years, they demonstrated an undesirably high rate of major adverse events and a high need for reinterventions. Due to the inclusion of patients from 1999 to 2001, these data reflect the early episode of TECAB procedures. Furthermore, the main part of the cohort was operated on beating heart. 22 A subsequent study from Jegaden et al. 23 investigated an inhomogeneous cohort of different strategies of minimally invasive myocardial revascularization in 160 patients. They described a survival rate of 96% at 3 years for the 59 patients in the TECAB group. Beside the small number of patients included and the relatively short duration of follow-up, evaluation of patency rate was only conducted on a symptom-based indication. 23 Currie et al. 20 provide evidence for a LIMA patency rate of 93% at a mean follow-up of 8 years. The study included different strategies of minimally invasive coronary revascularization with a relatively low sample size for each technique. The analysis intended to be representative for different forms of minimally invasive revascularization procedures, but comparisons of different groups remained completely unrespected. Therefore, data are of limited usefulness in daily clinical practice. 20 In a recent study of Yang et al., 7 long-term graft patency rate was investigated in 140 MIDCAB and 100 TECAB procedures. They were able to show excellent graft patency rates for each procedure. However, between 3 and 5 years after the procedure, just a small number of patients graft patency are reported for the TECAB group. In the current study, we could show very auspicious data regarding survival and the combined end point MACCE in a very homogeneous patient population. Even after 10 years, the rate of MACCE was comparable with conventional techniques. The main driving factor for MACCE was PCI. Under the consideration of the increase of multivessel TECAB due to growing expertise and improvement in robotic technology, the rate of PCI is expected to further decrease. 24 Patency rates after TECAB were still not sufficiently investigated. We could demonstrate an excellent patency rate of LIMA to LAD even after 10 years. These results are meeting current quality standards of conventional CABG and are in line with previous studies. 7, 25 In interpreting our results, it has to be kept in mind that all patients were operated using cardiac arrest and cardiopulmonary bypass. By their nature, TECAB procedures are technically highly demanding, even more for beating heart procedures. For this reason, most of our patients underwent intraoperative graft angiography to verify adequate graft function. As previously described, AH procedures are a major factor for successful realization of TECAB, especially during the early experience. 5 In contrast to all previously published reports, we present results of a very homogeneous patient cohort addressing only AH-TECAB procedures. Furthermore, our follow-up time and number of included patients are higher than in all previous reports. In addition, all our findings are comparable with survival rates and MACCE rates of large series of conventional CABG. 26 In summary, we provide encouraging results for AH-TECAB, which underline the great value of this procedure for highly selected patients.
Limitations of the Study
The main limitations of our study are as follows: first, we provide a long-term clinical and LIMA patency rate of AH-TECAB performed in highly selected patients, treated in a specialized center. Avoiding sternotomy and cardiopulmonary bypass are the ultimate goals of minimally invasive surgical revascularization. Improvements in robotic technology, anastomotic devices, and well-trained console surgeons may expand the indication to a higher-risk population. Nevertheless, at this date, an extrapolation of our results to patients with more complex coronary artery disease is not allowed. Second, only isolated LIMA to LAD AH-TECAB patients were considered for cCT in a consecutive matter, regardless of symptoms. Therefore, our results regarding LIMA patency do not cover the full range of AH-TECABs performed. Patients other than isolated LIMA to LAD AH-TECAB underwent cCT or coronary angiography only if they were symptomatic. The inclusion of data of these selected patients would therefore be biasing. Nevertheless, our report provides the longest LIMA patency rate of isolated LIMA to LAD AH-TECAB patients currently available. Third, we included only AH-TECAB patients in a single-arm analysis. A direct comparison with other forms of coronary revascularization was not possible. However, the strength of our report is the homogeneity of the cohort.
CONCLUSIONS
Taken together, we provide evidence for excellent clinical long-term results of patients undergoing AH-TECAB. Long-term LIMA patency is comparable with CABG through full sternotomy. 
